Germline CAG-repeat expansions mean that the children of individuals with Huntington’s disease would inherit CAG repeats that are longer than those in the previous generation, increasing the ...

Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to ...

Huntington's disease is a rare genetic, autosomal dominant, neurodegenerative disease, caused by CAG repeat expansions in the HTT gene, that is polymorphic on the healthy allele and contains more than ...

Alnylam Pharmaceuticals Inc. won a major FDA approval on Thursday, one that could propel the Cambridge company toward a major milestone — finally reaching profitability.

According to the University of California San Francisco, Huntington’s disease affects one in every 10,000 to 20,000 people in ...

While Huntington’s disease is progressive and worsens over time, understanding what is to come can help someone with this condition plan for the road ahead. Huntington’s disease is a ...

Just as cities must carefully manage the flow of cars in and out of downtown, cells regulate the movement of molecules into ...

Skyhawk presents today on its novel SKY-0515 small molecule RNA splicing modulator targeting Huntington's Disease to members of the Huntington's Disease Youth Organization, at the annual HYDO ...

Huntington's disease is a rare hereditary neurodegenerative disease affecting over 40,000 patients in the United States and many more worldwide. There are no approved treatments that can reverse ...

The Missouri Chapter of the Huntington's Disease Society of America will host a Team Hope walk Saturday, April 12, at Jackson ...

What initially seems like purely psychological trouble may indeed have roots in physical conditions that, once identified, ...